Skip to main content
OpenTrials
Completed

NCT Number: NCT07075796

Study of the Performance of the GLUCUBE System in Patients With Type 2 Diabetes

This study is a prospective, single center, open label clinical investigation. The primary objective of the study is to evaluate the performance of GLUCUBE in patients with diabetes type 2 and how the accuracy of the system improves as the time of use by the patient increases.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centro de Especialidades Virgen de los Reyes. Hospital Universitario Virgen del Rocío

Seville, 41001, Spain

About this study

Current methods of measuring blood glucose, glucometers, although minimally invasive, can be painful as they require puncturing the fingertip with a prick device and drawing a drop of blood, which is applied to a disposable test strip. This minimal invasiveness can cause discomfort and discourage the user from testing their blood glucose levels as frequently as necessary, leading to poor glycemic control. Due to the non-invasive nature of the GLUCUBE system, it provides glucose level information safely and painlessly, avoiding any discomfort to the user. It is low cost as it uses commonly used electronic components and does not require test strips or other consumables that would increase the ongoing cost of the device. The performance of the GLUCUBE system has already been evaluated in comparison to the standard glucometer (Ascensia Contour®Next) in adult patients with and without diabetes. The primary objective of this clinical investigation is to evaluate the performance of GLUCUBE in patients with diabetes type 2 and how the accuracy of the system improves as the time of use by the patient increases.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Be ≥ 18 years of age.
  • Diagnosed with type 2 diabetes mellitus.
  • Have a smartphone with an internet connection that allows the installation of the GLUCUBE APP.
  • Be able to use the GLUCUBE system autonomously, in the opinion of the researcher.
  • Have signed the informed consent.

Exclusion criteria

  • The patient is currently participating in another clinical investigation or has participated in another clinical investigation in the last 30 days prior to the start of this study.
  • Pregnant or breast-feeding women and those subjects who plan pregnancy during the clinical investigation follow-up period.
  • Presence of other anatomical or comorbid conditions, or other medical, social or psychological conditions that, in the opinion of the investigator, could limit the subject's ability to participate in the clinical investigation or to comply with the follow-up requirements, or affect the scientific soundness of the clinical investigation results.
  • Patients with any active and/or infectious acute illness.
  • Patients who have a condition that affects blood circulation in the fingers of the hand, such as Raynaud's phenomenon.
  • Any medical condition that, in the opinion of the investigator, will increase the risk of hyperglycemic and hypoglycemic events: seizures, heart disease, unconscious hypoglycemia, etc.
  • Patients with an inability to maintain hand stability during measurement or with progressive nervous system disease affecting movement (Parkinson's disease, moderate-severe essential tremor, and other diseases with involuntary movements).
  • Patients suffering from calluses, malformations, or open wounds with bandages on their hands.
  • Patients with nail polish or any type of false nail.

Treatment and study plan

GLUCUBE system

Device

A non-invasive system to monitor and measure the blood glucose compared to the standard glucometer in a group subjects

Primary outcomes

  1. Performance Evaluation

    Time frame: 4 times/day for 1 week

    Performance of the GLUCUBE device in monitoring and measuring blood glucose in adult patients with type 2 diabetes, compared to the standard glucometer (capillary blood glucometer - Ascensia Contour®Next).

  2. Performance Improvement Evaluation

    Time frame: through study completion, an average of 21 days

    Improved performance of the GLUCUBE device as patient usage time increases.

Other outcomes

  1. User Satisfaction

    Time frame: 21 days after the participant enters the study

    Evaluation of patient preferences for using the GLUCUBE system versus a capillary glucometer. Device(s) to be used in clinical research.

Sponsors and collaborators

Lead sponsor

iGluco

Industry

Registry information

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Jul 20, 2025
Registry last updated
Jan 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.